Skip to main content

Table 3 Association between mammographic density and current use of menopausal hormone therapy stratified by genotypes of ten SNPs showing the lowest P values for interaction

From: A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density

SNP SNP type Chr Gene Density measure Homozygous reference genotype (N) Heterozygous genotype (N) Homozygous non-reference genotype (N) P interaction
Betaa (95 % CI) P Betaa (95 % CI) P Betaa (95 % CI) P  
      T/T (2000)   T/G (3167)   G/G (1131)   
rs9358531 Imputed 6 6.5 kb 5′ of PRL PD 0.23 (0.08, 0.38) 2.5 × 10−03 0.46 (0.34, 0.58) 5.1 × 10−14 0.69 (0.49, 0.89) 1.4 × 10−11 0.0004
DA 0.38 (0.18, 0.58) 2.1 × 10−04 0.6 (0.44, 0.76) 1.2 × 10−13 0.85 (0.59, 1.12) 2.7 × 10−10 0.008
NDA −0.17 (−0.39, 0.05) 1.4 × 10−01 −0.29 (−0.47, −0.12) 1.2 × 10−03 −0.58 (−0.87, −0.29) 1.0 × 10−04 0.02
      G/G (2138)   G/A (3142)   A/A (1018)   
rs9356811 Imputed 6 5.2 kb 5′ of PRL PD 0.24 (0.1, 0.39) 1.1 × 10−03 0.48 (0.36, 0.6) 1.3 × 10−14 0.69 (0.48, 0.9) 1.5 × 10−10 0.0004
DA 0.39 (0.2, 0.59) 6.6 × 10−05 0.6 (0.44, 0.76) 1.9 × 10−13 0.89 (0.61, 1.17) 4.6 × 10−10 0.005
NDA −0.17 (−0.38, 0.05) 1.2 × 10−01 −0.33 (−0.51, −0.15) 2.5 × 10−04 −0.51 (−0.82, −0.2) 1.1 × 10−03 0.05
      C/C (2158)   C/T (3124)   T/T (1016)   
rs10946546 Imputed 6 17 kb 5′ of PRL PD 0.22 (0.07, 0.37) 3.2 × 10−03 0.51 (0.39, 0.63) 2.2 × 10−16 0.63 (0.42, 0.84) 3.0 × 10−09 0.0004
DA 0.39 (0.19, 0.58) 9.0 × 10−05 0.64 (0.48, 0.8) 4.8 × 10−15 0.77 (0.49, 1.05) 4.9 × 10−08 0.02
NDA −0.11 (−0.32, 0.1) 3.1 × 10−01 −0.37 (−0.55, −0.2) 3.4 × 10−05 −0.49 (−0.8, −0.19) 1.5 × 10−03 0.01
      T/T (2230)   T/C (3093)   C/C (975)   
rs9393273 Imputed 6 8.1 kb 5′ of PRL PD 0.24 (0.1, 0.39) 7.8 × 10−04 0.49 (0.37, 0.61) 4.8 × 10−15 0.68 (0.47, 0.89) 5.0 × 10−10 0.0005
DA 0.4 (0.21, 0.59) 3.6 × 10−05 0.62 (0.46, 0.78) 8.5 × 10−14 0.86 (0.58, 1.15) 2.4 × 10−09 0.01
NDA −0.16 (−0.37, 0.05) 1.3 × 10−01 −0.33 (−0.51, −0.16) 2.4 × 10−04 −0.54 (−0.85, −0.23) 6.9 × 10−04 0.03
      A/A (2079)   A/G (3154)   G/G (1065)   
rs12525289 Imputed 6 9.9 kb 5′ of PRL PD 0.24 (0.09, 0.39) 1.5 × 10−03 0.47 (0.35, 0.59) 2.0 × 10−14 0.68 (0.47, 0.88) 7.8 × 10−11 0.0005
DA 0.4 (0.2, 0.59) 7.3 × 10−05 0.59 (0.43, 0.76) 4.3 × 10−13 0.88 (0.61, 1.15) 2.1 × 10−10 0.009
NDA −0.14 (−0.35, 0.08) 2.1 × 10−01 −0.34 (−0.51, −0.16) 1.9 × 10−04 −0.53 (−0.82, −0.23) 5.4 × 10−04 0.03
      G/G (2090)   G/A (3142)   A/A (1066)   
rs12199382 Imputed 6 24 kb 5′ of PRL PD 0.21 (0.07, 0.36) 4.5 × 10−03 0.51 (0.39, 0.63) 1.8 × 10−16 0.62 (0.41, 0.82) 2.8 × 10−09 0.0006
DA 0.37 (0.17, 0.56) 2.5 × 10−04 0.65 (0.49, 0.81) 1.7 × 10−15 0.76 (0.49, 1.03) 3.5 × 10−08 0.02
NDA −0.13 (−0.35, 0.08) 2.2 × 10−01 −0.35 (−0.53, −0.17) 1.1 × 10−04 −0.49 (−0.79, −0.2) 1.1 × 10−03 0.02
      G/G (2629)   G/A (2873)   A/A (796)   
rs9542456 Genotyped 13 505 kb 3′ of ATXN8OS PD 0.59 (0.46, 0.73) 4.7 × 10−18 0.33 (0.2, 0.45) 4.1 × 10−07 0.22 (−0.01, 0.45) 5.9 × 10−02 0.0009
DA 0.75 (0.57, 0.93) 2.0 × 10−16 0.45 (0.28, 0.61) 1.8 × 10−07 0.44 (0.14, 0.75) 4.7 × 10−03 0.02
NDA −0.43 (−0.63, −0.24) 1.6 × 10−05 −0.27 (−0.45, −0.08) 4.7 × 10−03 0.02 (−0.32, 0.36) 9.2 × 10−01 0.02
      T/T (2241)   T/G (3092)   G/G (965)   
rs12524161 Imputed 6 46 kb 5′ of PRL PD 0.26 (0.12, 0.41) 2.8 × 10−04 0.47 (0.35, 0.6) 3.9 × 10−14 0.68 (0.47, 0.89) 4.6 × 10−10 0.001
DA 0.42 (0.23, 0.61) 1.2 × 10−05 0.6 (0.44, 0.76) 4.8 × 10−13 0.86 (0.58, 1.14) 2.6 × 10−09 0.01
NDA −0.14 (−0.35, 0.06) 1.7 × 10−01 −0.34 (−0.51, −0.16) 2.3 × 10−04 −0.57 (−0.88, −0.26) 3.3 × 10−04 0.02
      C/C (5358)   C/T (899)   T/T (41)   
rs17861099 Imputed 15 462 bp 5′ of CYP1A1 PD 0.48 (0.39, 0.58) 2.4 × 10−21 0.09 (−0.14, 0.32) 4.3 × 10−01 −0.22 (−1.8, 1.37) 7.9 × 10−01 0.001
DA 0.65 (0.52, 0.78) 1.1 × 10−21 0.13 (−0.17, 0.43) 3.9 × 10−01 0.01 (−2.09, 2.1) 9.9 × 10−01 0.002
NDA −0.35 (−0.5, −0.21) 1.8 × 10−06 0.02 (−0.32, 0.35) 9.2 × 10−01 −0.18 (−2.48, 2.13) 8.8 × 10−01 0.04
      G/G (5337)   G/A (923)   A/A (38)   
rs17861118 Imputed 15 8.3 kb 5′ of CYP1A1 PD 0.49 (0.39, 0.59) 2.6 × 10−21 0.1 (−0.12, 0.33) 3.8 × 10−01 −0.23 (−1.81, 1.35) 7.8 × 10−01 0.001
DA 0.66 (0.52, 0.79) 3.4 × 10−22 0.09 (−0.21, 0.39) 5.6 × 10−01 −0.02 (−2.11, 2.08) 9.9 × 10−01 0.0006
NDA −0.34 (−0.49, −0.19) 5.0 × 10−06 −0.08 (−0.41, 0.24) 6.1 × 10−01 −0.18 (−2.48, 2.13) 8.8 × 10−01 0.08
  1. aAdjusted for study, reference age, case status, former use of menopausal hormone therapy, body mass index, number of pregnancies and principal components. SNP single nucleotide polymorphism, Chr chromosome, PD percent density (%), square-root-transformed, DA dense area (cm2), square-root-transformed, NDA non-dense area (cm2), square-root-transformed